Exelixis Explains Virtues Of Flat Pricing For Cometriq
This article was originally published in The Pink Sheet Daily
Approval in very rare medullary thyroid cancer marks an important milestone for Exelixis’ Cometriq (cabozantinib), which is being positioned for multiple cancers. The company will need only five sales reps for the thyroid cancer market and plans to launch in late January 2013 at the price of $9,900 per 28 days.
You may also be interested in...
Panelists with a variety of strategic motives met to discuss the pros and cons of business models at the Cancer Progress Meeting in New York City. The group represented both new and old firms, including some that perform research and some that license drugs.
Gilead reports the results from a fourth Phase III pivotal trial for its HCV drug that will lead to a 2013 filing, while Meda, Curis, and Intermune discuss drug launches.
As cabozantinib wins FDA approval for the rare medullary thyroid cancer, Exelixis stresses its broader development program in other tumor types, notably prostate cancer. The company is likely to submit prostate cancer data to compendia, which if successful could enable reimbursement for the off-label use.